Recombinant human erythropoietin improves neurological outcomes in very preterm infants

Annals of Neurology

Volumn 80, Issue 1, 2016, Pages 24-34

  Song, Juan ^a   Sun, Huiqing ^b   Xu, Falin ^a,c   Kang, Wenqing ^b   Gao, Liang ^a   Guo, Jiajia ^a   Zhang, Yanhua ^a   Xia, Lei ^a   Wang, Xiaoyang ^a,d   Zhu, Changlian ^a,b,c,d  

^a ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU CHILDREN S HOSPITAL   (China)

^c Key Laboratory of Neonatal Brain Injury of Henan Province   (China)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BAYLEY SCALES OF INFANT DEVELOPMENT; BRAIN DEVELOPMENT; BRAIN FUNCTION; BRAIN HEMORRHAGE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENCEPHALOMALACIA; ERYTHROCYTE COUNT; EVALUATION STUDY; FEMALE; GESTATIONAL AGE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INFANT; INFANT MORTALITY; LOW DRUG DOSE; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NECROTIZING ENTEROCOLITIS; NEUROLOGIC DISEASE; NEWBORN SEPSIS; OUTCOME ASSESSMENT; POLYCYTHEMIA; PREMATURITY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETROLENTAL FIBROPLASIA; SIDE EFFECT; THROMBOCYTE COUNT; VEIN THROMBOSIS;

EID: 84977647289     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24677     Document Type: Article

References (50)

1. Kinney MV, Lawn JE, Howson CP, Belizan J. 15 Million preterm births annually: what has changed this year? Reprod Health 2012;9:28.
2. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012;379:2151–2161.
3. Serenius F, Kallen K, Blennow M, et al. Neurodevelopmental outcome in extremely preterm infants at 2.5 years after active perinatal care in Sweden. JAMA 2013;309:1810–1820.
4. Hintz SR, Kendrick DE, Wilson-Costello DE, et al. Early-childhood neurodevelopmental outcomes are not improving for infants born at <25 weeks' gestational age. Pediatrics 2011;127:62–70.
5. Juul SE, Ferriero DM. Pharmacologic neuroprotective strategies in neonatal brain injury. Clin Perinatol 2014;41:119–131.
6. Maier RF, Obladen M, Muller-Hansen I, et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr 2002;141:8–15.
7. Sargin D, El-Kordi A, Agarwal A, et al. Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice. BMC Biol 2011;9:27.
8. Zhu C, Kang W, Xu F, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 2009;124:e218–e226.
9. Traudt CM, McPherson RJ, Bauer LA, et al. Concurrent erythropoietin and hypothermia treatment improve outcomes in a term nonhuman primate model of perinatal asphyxia. Dev Neurosci 2013;35:491–503.
10. Hellstrom-Westas L, Rosen I. Continuous brain-function monitoring: state of the art in clinical practice. Semin Fetal Neonatal Med 2006;11:503–511.
11. Siren AL, Knerlich F, Poser W, et al. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001;101:271–276.
12. Wang X, Zhu C, Wang X, et al. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem 2004;91:900–910.
13. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239–242.
14. Wu YW, Bauer LA, Ballard RA, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 2012;130:683–691.
15. Elmahdy H, El-Mashad AR, El-Bahrawy H, et al. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics 2010;125:e1135–e1142.
16. Leuchter RH, Gui L, Poncet A, et al. Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. JAMA 2014;312:817–824.
17. Neubauer AP, Voss W, Wachtendorf M, Jungmann T. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Ann Neurol 2010;67:657–666.
18. Rosebraugh MR, Widness JA, Nalbant D, et al. Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants. Pediatr Res 2014;75:336–342.
19. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2012;10:CD004865.
20. Juul SE, McPherson RJ, Bauer LA, et al. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008;122:383–391.
21. Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006;118:e635–e640.
22. Kandasamy Y, Kumar P, Hartley L. The effect of erythropoietin on the severity of retinopathy of prematurity. Eye 2014;28:814–818.
23. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2014;4:CD004863.
24. Ballot DE, Potterton J, Chirwa T, et al. Developmental outcome of very low birth weight infants in a developing country. BMC Pediatr 2012;12:11.
25. Vazquez Lopez MA, Llamas MA, Galera R, et al. Comparison between one and three doses a week of recombinant erythropoietin in very low birth weight infants. J Perinatol 2011;31:118–124.
26. Song J, Xu F, Wang L, et al. Early amplitude-integrated electroencephalography predicts brain injury and neurological outcome in very preterm infants. Sci Rep 2015;5:13810.
27. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529–534.
28. de Vries LS, Eken P, Dubowitz LM. The spectrum of leukomalacia using cranial ultrasound. Behav Brain Res 1992;49:1–6.
29. Smyser CD, Snyder AZ, Shimony JS, et al. Effects of white matter injury on resting state fMRI measures in prematurely born infants. PLoS One 2013;8:e68098.
30. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116:1353–1360.
31. Berman L, Moss RL. Necrotizing enterocolitis: an update. Semin Fetal Neonatal Med 2011;16:145–150.
32. Yu XD, Branch DW, Karumanchi SA, Zhang J. Preeclampsia and retinopathy of prematurity in preterm births. Pediatrics 2012;130:e101–e107.
33. McAdams RM, McPherson RJ, Mayock DE, Juul SE. Outcomes of extremely low birth weight infants given early high-dose erythropoietin. J Perinatol 2013;33:226–230.
34. Fan X, Heijnen CJ, van der KM, et al. Beneficial effect of erythropoietin on sensorimotor function and white matter after hypoxia-ischemia in neonatal mice. Pediatr Res 2011;69:56–61.
35. Liu W, Shen Y, Plane JM, et al. Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. Exp Neurol 2011;230:227–239.
36. O'Gorman RL, Bucher HU, Held U, et al. Tract-based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain 2015;138(pt 2):388–397.
37. Fauchere JC, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008;122:375–382.
38. Ohls RK, Kamath-Rayne BD, Christensen RD, et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics 2014;133:1023–1030.
39. Larroque B, Ancel PY, Marret S, et al. Neurodevelopmental disabilities and special care of 5-year-old children born before 33 weeks of gestation (the EPIPAGE study): a longitudinal cohort study. Lancet 2008;371:813–820.
40. Xia L, Sun L, Wang X, et al. Changes in the incidence of congenital anomalies in Henan Province, China, from 1997 to 2011. PLoS One 2015;10:e0131874.
41. Peacock JL, Marston L, Marlow N, et al. Neonatal and infant outcome in boys and girls born very prematurely. Pediatr Res 2012;71:305–310.
42. Fauchere JC, Koller BM, Tschopp A, et al. Safety of early high-dose recombinant erythropoietin for neuroprotection in very preterm infants. J Pediatr 2015;167:52–57.
43. Marlow N, Morris T, Brocklehurst P, et al. A randomised trial of granulocyte-macrophage colony-stimulating factor for neonatal sepsis: childhood outcomes at 5 years. Arch Dis Child Fetal Neonatal Ed 2015;100:F320–F326.
44. Ohls RK, Roohi M, Peceny HM, et al. A randomized, masked study of weekly erythropoietin dosing in preterm infants. J Pediatr 2012;160:790–795.
45. Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res 2007;61:451–455.
46. Brown MS, Eichorst D, Lala-Black B, Gonzalez R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. Pediatrics 2009;124:e681–e687.
47. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782–792.
48. Schneider JK, Gardner DK, Cordero L. Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low-birth-weight infants. Pharmacotherapy 2008;28:1335–1340.
49. Shiou SR, Yu Y, Chen S, et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. J Biol Chem 2011;286:12123–12132.
50. Vollmar B, Eipel C, Menger MD. Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med 2010;38:340–341.